Maria J Suarez1, Roxana Rivera-Michlig2, Sander Dubovy3, Fausto J Rodriguez4. 1. Department of Pathology, Miami, Fla., USA. 2. Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Md., USA. 3. Bascom Palmer Eye Institute, University of Miami, Miami, Fla., USA. 4. Department of Pathology, Miami, Fla., USA; Sidney Kimmel Comprehensive Cancer Center, Miami, Fla., USA.
Abstract
BACKGROUND: Patients with xeroderma pigmentosum (XP) are strongly predisposed to the development of numerous cutaneous cancers. However, the extent of ocular pathology in these patients has not been adequately studied. METHODS: We conducted a retrospective study of tumors involving the ocular surface and ocular adnexa from 6 XP patients. Histopathological evaluation and immunohistochemistry was performed using antibodies directed against the most common mutated proteins in XP (XPA, XPC, and XPD). RESULTS: Patients included 4 males and 2 females with a mean age of 20.8 years (range 10-31) who met the clinical criteria for XP and were found to have a total of 13 neoplasms involving the ocular surface and adnexal skin; 6 squamous cell carcinomas (SCC), 3 cases of conjunctival intraepithelial neoplasia, 2 malignant melanomas, 1 basal cell carcinoma, and 1 atypical fibroxanthoma. Complete XPD loss was present in two tumors from 1 patient, suggesting a germline defect, and in the invasive component of an SCC from a second patient, suggesting a somatic alteration. No clear pattern of loss for XPA or XPC was evident. CONCLUSIONS: Our study outlines our early experience with the pathology of ocular neoplasms in XP patients. These findings deserve further exploration with genetic studies and additional patients.
BACKGROUND:Patients with xeroderma pigmentosum (XP) are strongly predisposed to the development of numerous cutaneous cancers. However, the extent of ocular pathology in these patients has not been adequately studied. METHODS: We conducted a retrospective study of tumors involving the ocular surface and ocular adnexa from 6 XP patients. Histopathological evaluation and immunohistochemistry was performed using antibodies directed against the most common mutated proteins in XP (XPA, XPC, and XPD). RESULTS:Patients included 4 males and 2 females with a mean age of 20.8 years (range 10-31) who met the clinical criteria for XP and were found to have a total of 13 neoplasms involving the ocular surface and adnexal skin; 6 squamous cell carcinomas (SCC), 3 cases of conjunctival intraepithelial neoplasia, 2 malignant melanomas, 1 basal cell carcinoma, and 1 atypical fibroxanthoma. Complete XPD loss was present in two tumors from 1 patient, suggesting a germline defect, and in the invasive component of an SCC from a second patient, suggesting a somatic alteration. No clear pattern of loss for XPA or XPC was evident. CONCLUSIONS: Our study outlines our early experience with the pathology of ocular neoplasms in XP patients. These findings deserve further exploration with genetic studies and additional patients.
Authors: Hema L Ramkumar; Brian P Brooks; Xiaoguang Cao; Deborah Tamura; John J Digiovanna; Kenneth H Kraemer; Chi-Chao Chan Journal: Surv Ophthalmol Date: 2011 Jul-Aug Impact factor: 6.048
Authors: Brian P Brooks; Amy H Thompson; Rachel J Bishop; Janine A Clayton; Chi-Chao Chan; Ekaterini T Tsilou; Wadih M Zein; Deborah Tamura; Sikandar G Khan; Takahiro Ueda; Jennifer Boyle; Kyu-Seon Oh; Kyoko Imoto; Hiroki Inui; Shin-Ichi Moriwaki; Steffen Emmert; Nicholas T Iliff; Porcia Bradford; John J Digiovanna; Kenneth H Kraemer Journal: Ophthalmology Date: 2013-04-16 Impact factor: 12.079
Authors: Sébastien de Feraudy; Imenne Boubakour-Azzouz; Sylvie Fraitag; Mark Berneburg; Loretta Chan; Kevin Chew; Carol L Clericuzio; Bari Cunningham; Whitney D Tope; James E Cleaver Journal: Am J Dermatopathol Date: 2010-04 Impact factor: 1.533
Authors: M Adelita Vizcaino; Abeer Z Tabbarah; Laura Asnaghi; Azza Maktabi; Allen O Eghrari; Divya Srikumaran; Charles G Eberhart; Fausto J Rodriguez Journal: Hum Pathol Date: 2019-09-05 Impact factor: 3.466
Authors: Elizabeth R H Rizza; John J DiGiovanna; Sikandar G Khan; Deborah Tamura; Jack D Jeskey; Kenneth H Kraemer Journal: J Invest Dermatol Date: 2021-01-09 Impact factor: 8.551